Founded in 2006, Zosano Pharma, formerly known as The Macroflux Corporation, is a private pharmaceutical company. It is involved in the development and commercialization of therapeutic drug candidates. The company's parathyroid hormone transdermal microprojection delivery system provides needle-free administration with room temperature stability for various therapeutic peptides, proteins, small molecules and vaccines. Zosano Pharma works in association with various pharmaceutical companies to pursue product partnership programs. It has more than 10 patent families and offers products under the Zosano Pharma and Macroflux brands. The company has a work force of over 40 employees. Zosano Pharma receives funds from ProQuest Investments and Nomura Phase4 Ventures Limited.